Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCap-xx Regulatory News (CPX)

Share Price Information for Cap-xx (CPX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.0855
Bid: 0.085
Ask: 0.086
Change: -0.0075 (-8.11%)
Spread: 0.001 (1.176%)
Open: 0.0925
High: 0.095
Low: 0.085
Prev. Close: 0.0925
CPX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Trading Update

3 Nov 2023 07:05

RNS Number : 2716S
CAP-XX Limited
03 November 2023
 

Dissemination of a Regulatory Announcement that contains inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.

 

3 November 2023

CAP-XX Limited

("CAP-XX" or "the Company")

AGM Trading Update

CAP-XX Limited, a world leader in the design and manufacture of supercapacitors and energy management systems, announces that at the Company's Annual General Meeting to be held later today, the following statement will be made in relation to the Company's activities.

Current Sales

Preliminary October 2023 product revenue was US$0.4m (approximately AUD$0.6m) and for the four months to the end of October 2023 was US$0.9m (AUD$1.5m). This compares with product revenues of US$0.7m (AUD$1.1m) in the previous corresponding four month period of last year, a year on year increase of approximately 35%.

October is typically one of the highest revenue months for the financial year and this revenue result is an early indicator that the overstocking and supply chain issues that were evident during FY2023 are showing signs of recovery.

Order Intake

CAP-XX's sales priorities remain focused on prismatic Electric Double Layer Capacitor (EDLC) and cylindrical 'can' business, followed by customer module solutions.

The Company is seeing an increase in activity and interest in CAP-XX's products from the USA, Europe, India as well as South Africa and this is evidenced by a marked increase in the request for samples across the product range, especially in Europe and the USA. Activities in Asia remain subdued due to the economic situation post COVID.

The current order backlog is US$1.15 million and order intake is supportive of a further improvement in revenues.

Enquiries and orders from Europe and the USA are higher, but we are experiencing some slower order intake from China and India, primarily for the cylindrical 'can' products where the overstocking position of many customers/distributors has not yet fully worked through.

Distribution and Sales Strategy

We have made good progress in building our new sales and distribution capabilities. We have appointed additional distributors and sales representatives mainly in the USA, Europe and India. There are further appointments currently in final negotiations which are expected to be completed by calendar year-end 2023. These new distributors and sales representatives are commission based and have been trained in relation to the CAP-XX product range and we expect to see revenue results progressively build through calendar 2024.

The whole CAP-XX team is working hard to ensure that a strong focus on the customer is maintained, in addition to building good relationships with suppliers, distributors and sales representatives.

CAP-XX will remain focused on Internet of Things (IoT), automotive, medical, military, industrial and telecom applications and associated markets with a particular concentration on handheld devices, tracking, security and live aid systems.

New Product Development

We continue to advance our new products, specifically DMH, 3V and SMD. The DMH product samples are on track for delivery by calendar year-end 2023, with commercial production expected to commence in early calendar year 2024. First orders are already in hand with several other customers evaluating the product.

The 3V product continues to be evaluated by several potential large volume customers and we continue to expect design wins, with initial orders expected in the first half of calendar year 2024.

The cylindrical SMD device is continuing through development trials and we anticipate design wins through the remainder of 2023/24, with full commercial production scheduled for 2024/25.

In addition to these new products that we have been working on for some time, we have re-formatted some EDLC prismatic supercapacitors as embedded versions, which allows our customers to use our technology as a plug and play solution.

Intellectual Property

We are well advanced in the final evaluation of the Ionic graphene product and are currently in joint venture negotiations. We are also actively evaluating other technologies that are complementary to our own.

The Maxwell legal case is currently set for hearing from 11 to 15 December 2023 in the US Supreme Court. We are unable to make any further comment at this time, except that our team is very well prepared.

We last received royalty payments from AVX in January 2023 for the 2022 year. We have been disputing the contract interpretation adopted by AVX and there are preliminary court hearings underway. The Company's position has not altered, and we remain confident of a favorable outcome in both cases.

Quality Certification

CAP-XX is very conscious of the need to have the highest level of quality compliance in place. We already have ISO 9001 certification covering quality management systems and are actively working to achieve ISO 14001 which covers environmental management systems. The Company views these as essential standards aimed at meeting customers' requirements and expectations.

Production

Operating performance at Seven Hills and our contract manufacturer in Malaysia is improving. However, there are more gains to be made through programs of continuous improvement.

Cash

Currently, cash reserves are approximately AUD$0.5m, excluding the Australian Tax R&D Rebate for 2022/23. The rebate was formally submitted in October 2023, and a payment of AUD$2.1m is expected to be received in the coming weeks.

Outlook

As highlighted in the Annual Report, CAP-XX is reviewing the current sales project pipeline, including feasibility studies and timelines.

We expect to see the new distribution and sales strategy begin to demonstrate positive results in the coming months. We are seeing product revenues improving and, barring a general economic downturn, we expect this to continue.

Finally, the Company is keenly looking forward to the initial revenues from new products in which the Company has made significant investments over recent years.

 

 

For further information contact:

CAP-XX Limited

Pat Elliott (Chairman)

Lars Stegmann (CEO)

 

+61 (0) 2 9428 0139

Kreab (Financial PR)

Robert Speed

 

+44 (0) 20 7074 1800

Allenby Capital (Nominated Adviser and Joint Broker)

David Hart / Piers Shimwell (Corporate Finance)

Tony Quirke/Stefano Aquilino (Sales and Corporate Broking)

 

+44 (0) 20 3328 5656

Cavendish Securities plc (Joint Broker)

Neil McDonald / Pearl Kellie

 

+44 (0) 13 1220 6939

 

More information is available at www.cap-xx.com

 

Notes to Editors:

 

CAP-XX (LSE:CPX) is a world leader in the design and manufacture of ultra-thin prismatic and compact cylindrical supercapacitors. Its prismatic supercapacitors are manufactured in Australia and Malaysia and its cylindrical supercapacitors are manufactured in China. The company's strong intellectual property (IP) portfolio includes 11 patent families. CAP-XX's ultra-thin prismatic supercapacitors are ideal for space-constrained electronics applications where small energy storage device size and thickness are important. The unique feature of CAP-XX supercapacitors is their very high-power density and high-energy storage capacity in space-efficient thin prismatic and compact cylindrical packages. For more information, visit https://www.cap-xx.com/ or email sales@cap-xx.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTNKBBNNBDBFDK
Date   Source Headline
25th Apr 20249:24 amRNSHolding(s) in Company
24th Apr 20245:04 pmRNSN05/24 - CAP-XX Limited - Restoration of trading
23rd Apr 20248:36 amRNSResult of General Meeting
8th Apr 20249:12 amRNSLitigation with Kyocera AVX settled
28th Mar 20245:00 pmRNSTotal Voting Rights
27th Mar 20248:22 amRNSSuspension of trading
27th Mar 20247:29 amRNSN04/24 - CAP-XX Limited - Suspension of trading
25th Mar 20247:00 amRNSResult of Retail Offer and Total Voting Rights
22nd Mar 20247:00 amRNSResult of Placing and Notice of General Meeting
21st Mar 20244:40 pmRNSREX Retail Offer
21st Mar 20244:35 pmRNSProposed Placing and Subscription to raise £2.0m
21st Mar 20249:00 amRNSLitigation Settlement Agreement with Tesla, Inc
19th Mar 202412:31 pmRNSHolding(s) in Company
18th Mar 20242:56 pmRNSHolding(s) in Company
15th Mar 202412:50 pmRNSHolding(s) in Company
15th Mar 20247:07 amRNSHolding(s) in Company
14th Mar 20247:00 amRNSUpdate on litigation
13th Mar 20247:00 amRNSCorporate Update
12th Mar 20247:00 amRNSRetirement of CFO
28th Feb 20247:00 amRNSUpdate on litigation and trading
19th Feb 20247:00 amRNSCessation of appeals process
1st Feb 20247:00 amRNSInterim Results
29th Jan 20247:00 amRNSUpdate on Patent Infringement
22nd Jan 202412:57 pmRNSChange of Joint Broker
10th Jan 20247:02 amRNSUpdate on IP and appeals process
29th Dec 20231:00 pmRNSTotal Voting Rights
21st Dec 20237:00 amRNSTrading Update
18th Dec 20237:00 amRNSUpdate on Patent Infringement
7th Dec 20237:00 amRNSCAP-XX finalises two new patents
5th Dec 20237:00 amRNSIssue of Shares and Director/PDMR Shareholdings
1st Dec 20237:00 amRNSUpdate re. R&D rebate and other matters
29th Nov 20237:00 amRNSHolding(s) in Company
22nd Nov 202311:29 amRNSHolding(s) in Company
3rd Nov 20239:05 amRNSResult of AGM and Directorate Change
3rd Nov 20237:05 amRNSAGM Trading Update
26th Oct 20232:05 pmRNSHolding(s) in Company
13th Oct 20239:45 amRNSNotice of AGM
4th Oct 20237:00 amRNSExpansion of sales operations
29th Sep 20237:00 amRNSAudited results for the year ended 30 June 2023
14th Sep 202312:29 pmRNSHolding(s) in Company
2nd Aug 20237:00 amRNSPre-close Trading Update and Notice of Results
31st Jul 20239:53 amRNSHolding(s) in Company
18th Jul 202310:27 amRNSUpdate on Patent Infringement
30th Jun 20235:00 pmRNSTotal Voting Rights
13th Jun 20237:00 amRNSHolding(s) in Company
9th Jun 20237:53 amRNSAppointment of Chief Executive Officer
8th Jun 20238:38 amRNSHolding(s) in Company
8th Jun 20237:00 amRNSHolding(s) in Company
6th Jun 202311:38 amRNSHolding(s) in Company
2nd Jun 20238:36 amRNSResult of General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.